v3.26.1

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 80,887	$ 100,547
Accounts receivable	10,627
Prepaid expenses and other current assets	5,048	5,039
Total current assets	96,562	105,586
Property and equipment, net	25,960	27,672
Operating lease right-of-use assets	8,763	9,417
Other noncurrent assets	3,785	4,246
Total assets	135,070	146,921
Current liabilities:
Accounts payable	1,914	3,581
Accrued and other current liabilities	6,030	8,835
Contract liabilities, current	5,722
Operating lease liabilities, current	3,115	3,020
Total current liabilities	16,781	15,436
Contract liabilities, noncurrent	4,680
Operating lease liabilities, noncurrent	7,002	7,810
Other noncurrent liabilities	418	410
Total liabilities	28,881	23,656
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 216,998,876 and 216,760,283 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	21	21
Additional paid-in capital	730,448	728,252
Accumulated deficit	(624,280)	(605,008)
Total stockholders' equity	106,189	123,265
Total liabilities and stockholders' equity	$ 135,070	$ 146,921

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Tenaya Therapeutics, Inc. 10-Q